FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168486977> ?p ?o ?g. }

• W2168486977 abstract "In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the peptibody trebananib, the multikinase inhibitors pazopanib, nintedanib, cediranib, sunitinib, and sorafenib were developed to interfere with VEGF receptors and multiple additional intracellular pathways. Nintedanib and pazopanib significantly improved progression-free survival in two positive phase III trials for firstline therapy. A reliable effect on overall survival could, however, not be observed for any anti-angiogenic firstline therapies so far. In terms of recurrent disease, two positive phase III trials revealed that trebananib and cediranib are effective anti-angiogenic agents for this indication. Patient selection and biomarker guided prediction of response seems to be a central aspect for future studies. Combining anti-angiogenics with other targeted therapies to possibly spare chemotherapy in certain constellations, represents another very interesting future perspective for clinical trials. This short review gives an overview of current clinical trials for anti-angiogenic treatment strategies beyond bevacizumab. In this context, possible future perspectives combining anti-angiogenics with other targeted therapies and the need for specific biomarkers predicting response are elucidated." @default.
• W2168486977 created "2016-06-24" @default.
• W2168486977 creator A5011977412 @default.
• W2168486977 creator A5021290996 @default.
• W2168486977 creator A5022606829 @default.
• W2168486977 creator A5042711497 @default.
• W2168486977 creator A5049873842 @default.
• W2168486977 creator A5056412323 @default.
• W2168486977 creator A5069415804 @default.
• W2168486977 creator A5091217089 @default.
• W2168486977 date "2015-10-05" @default.
• W2168486977 modified "2023-10-14" @default.
• W2168486977 title "Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer" @default.
• W2168486977 cites W1490550714 @default.
• W2168486977 cites W1980725734 @default.
• W2168486977 cites W1983150990 @default.
• W2168486977 cites W1994855668 @default.
• W2168486977 cites W1997761243 @default.
• W2168486977 cites W2002064506 @default.
• W2168486977 cites W2011264584 @default.
• W2168486977 cites W2026697154 @default.
• W2168486977 cites W2040327667 @default.
• W2168486977 cites W2061345986 @default.
• W2168486977 cites W2102195694 @default.
• W2168486977 cites W2109400578 @default.
• W2168486977 cites W2111147673 @default.
• W2168486977 cites W2113122060 @default.
• W2168486977 cites W2123334268 @default.
• W2168486977 cites W2128178813 @default.
• W2168486977 cites W2132193955 @default.
• W2168486977 cites W2133537644 @default.
• W2168486977 cites W2134021845 @default.
• W2168486977 cites W2135947389 @default.
• W2168486977 cites W2150654881 @default.
• W2168486977 cites W2150683293 @default.
• W2168486977 cites W2151509048 @default.
• W2168486977 cites W2154056804 @default.
• W2168486977 cites W2170928115 @default.
• W2168486977 cites W2171658624 @default.
• W2168486977 cites W2346236028 @default.
• W2168486977 doi "https://doi.org/10.3389/fonc.2015.00211" @default.
• W2168486977 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4593253" @default.
• W2168486977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26500886" @default.
• W2168486977 hasPublicationYear "2015" @default.
• W2168486977 type Work @default.
• W2168486977 sameAs 2168486977 @default.
• W2168486977 citedByCount "14" @default.
• W2168486977 countsByYear W21684869772015 @default.
• W2168486977 countsByYear W21684869772016 @default.
• W2168486977 countsByYear W21684869772017 @default.
• W2168486977 countsByYear W21684869772018 @default.
• W2168486977 countsByYear W21684869772019 @default.
• W2168486977 countsByYear W21684869772020 @default.
• W2168486977 countsByYear W21684869772021 @default.
• W2168486977 crossrefType "journal-article" @default.
• W2168486977 hasAuthorship W2168486977A5011977412 @default.
• W2168486977 hasAuthorship W2168486977A5021290996 @default.
• W2168486977 hasAuthorship W2168486977A5022606829 @default.
• W2168486977 hasAuthorship W2168486977A5042711497 @default.
• W2168486977 hasAuthorship W2168486977A5049873842 @default.
• W2168486977 hasAuthorship W2168486977A5056412323 @default.
• W2168486977 hasAuthorship W2168486977A5069415804 @default.
• W2168486977 hasAuthorship W2168486977A5091217089 @default.
• W2168486977 hasBestOaLocation W21684869771 @default.
• W2168486977 hasConcept C121608353 @default.
• W2168486977 hasConcept C126322002 @default.
• W2168486977 hasConcept C143998085 @default.
• W2168486977 hasConcept C151730666 @default.
• W2168486977 hasConcept C167734588 @default.
• W2168486977 hasConcept C2776694085 @default.
• W2168486977 hasConcept C2777025900 @default.
• W2168486977 hasConcept C2777472916 @default.
• W2168486977 hasConcept C2777714996 @default.
• W2168486977 hasConcept C2777802072 @default.
• W2168486977 hasConcept C2778019345 @default.
• W2168486977 hasConcept C2778341716 @default.
• W2168486977 hasConcept C2778439243 @default.
• W2168486977 hasConcept C2778695046 @default.
• W2168486977 hasConcept C2778749236 @default.
• W2168486977 hasConcept C2779343474 @default.
• W2168486977 hasConcept C2779490328 @default.
• W2168486977 hasConcept C2780171596 @default.
• W2168486977 hasConcept C2780427987 @default.
• W2168486977 hasConcept C535046627 @default.
• W2168486977 hasConcept C71924100 @default.
• W2168486977 hasConcept C86803240 @default.
• W2168486977 hasConcept C98274493 @default.
• W2168486977 hasConceptScore W2168486977C121608353 @default.
• W2168486977 hasConceptScore W2168486977C126322002 @default.
• W2168486977 hasConceptScore W2168486977C143998085 @default.
• W2168486977 hasConceptScore W2168486977C151730666 @default.
• W2168486977 hasConceptScore W2168486977C167734588 @default.
• W2168486977 hasConceptScore W2168486977C2776694085 @default.
• W2168486977 hasConceptScore W2168486977C2777025900 @default.
• W2168486977 hasConceptScore W2168486977C2777472916 @default.
• W2168486977 hasConceptScore W2168486977C2777714996 @default.
• W2168486977 hasConceptScore W2168486977C2777802072 @default.
• W2168486977 hasConceptScore W2168486977C2778019345 @default.
• W2168486977 hasConceptScore W2168486977C2778341716 @default.
• W2168486977 hasConceptScore W2168486977C2778439243 @default.

• next